You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三生製藥(01530.HK)與輝瑞許可協議生效 折讓17%發新股籌7.85億
阿思達克 07-24 22:04
三生製藥(01530.HK)公布,公司與輝瑞(PFE.US)就PD-1/VEGF雙特異性抗體(SSGJ-707)訂立的許可協議之所有先決條件已達成,許可協議自7月24日起生效。同日,雙方訂立認購協議,向輝瑞發行3,114.25萬股,每股作價25.2055元,較今日(24日)收報折讓17.09%,總金額約7.85億元。完成後,輝瑞將持有公司股本1.28%。 所得淨額約80%用於豐富產品管線中的臨床及臨床前項目的全球研發佈局,以及改善生產設施;餘額撥作一般公司用途。de/d)~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account